With a UK trial for Rituximab at least temporarily in doubt, let’s turn the focus to Ampligen – a drug that is potentially one trial away from being approved for ME/CFS. Ampligen is still the only drug that’s been able to move the needle on exercise in ME/CFS.
With NIH director Collins making noises about a possible Ampligen trial and a new review paper out, it’s time to make the case for Ampligen.
Check out a Simmaron Research Foundation sponsored blog:
Over a million users visited Health Rising’s 1,000 blogs, posts and pages last year. HR was able to achieve this with a small budget (@ $40,000/year) which supported one full-time and one part-time person, several volunteers (and one busy website).
The difference Health Rising could make, however, could be so much greater. Please support Health Rising with your recurring (as low as $5/month) or one-time donations, and help it spread the word on these disease’s needs, their findings and treatments. Find out more here..